Vion Pharmaceuticals Reports 2009 First Quart...((A Development Stage Company) ...),Health

Date:5/11/2009

(A Development Stage Company) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, (In thousands, except per share data) 2009 2008 (Unaudited) Technology license fee revenue $5 $14 Operating expenses: Clinical trials 1,021 2,854 Other research and development 1,980 2,259 Total research and development 3,001 5,113 Marketing, general and administrative 1,616 2,087 Total operating expenses 4,617 7,200 Loss from operations (4,612) (7,186) Interest income 7 502 Interest expense (2,344) (1,505) Other income (expense), net 2,652 (6) Loss before income taxes (4,297) (8,195) Income tax provision (benefit) -- -- Net loss ($4,297) ($8,195) Basic and diluted loss per share(1) ($0.54) ($1.14) Weighted-average number of shares of common stock outstanding(1) 7,944 7,173 (1) Adjusted for all periods presented to reflect the Company's one-for-ten reverse stock split effected February 20, 2008. CONDENSED CONSOLIDATED BALANCE SHEET DATA Mar 31, Dec 31, (In thousands) 2009 2008
'/>"/>

SOURCE Vion Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
2. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
5. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
6. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
8. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
9. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
10. Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program